Understanding Mesothelioma: Clues from Calretinin for Patients

ByHolly Zink
Understanding Mesothelioma: Clues from Calretinin for Patients

Malignant mesothelioma is a tough cancer caused by asbestos. It’s hard to treat because it grows quickly and is tough to beat. A recent study took a close look at a protein called calretinin. Scientists wanted to see if it could help predict how long someone might live with this cancer and how well they might respond to treatment.

A Possible Game-Changer in Mesothelioma Care

The study looked at 265 patients with this mesothelioma. They checked how much calretinin was in their blood and looked at the genes linked to how calretinin works. Scientists used tests to measure calretinin and found differences in genes among patients. Then they checked if these things were connected to how long patients lived or how well they responded to chemotherapy.

Higher calretinin levels lead to shorter times without the cancer growing and shorter overall survival. But when they looked at other patient factors, this link wasn’t as strong. But, certain differences in genes still seemed connected to how long patients lived, even after considering other factors.

Patients with high calretinin levels were more likely to see the cancer grow again after cisplatin treatment. Having a calretinin level higher than 0.89 ng/mL was linked to a lower chance of survival during treatment. This is even when considering other things about the patients. Also, one of the gene differences, MIR335 rs3807348, seemed to show that patients might respond better to treatment.

Predicting Mesothelioma Results

Calretinin, a protein marker, has been useful in finding malignant mesothelioma. And it helps tell mesothelioma apart from other conditions caused by asbestos. But until now, we didn’t know much about how it might predict how long someone might live with this cancer or how well they might respond to treatment.

This study shows that treating malignant mesothelioma is tricky. Regular treatments like chemotherapy, surgery, and radiation haven’t improved how long patients live. Learning about markers like calretinin could help make personalized treatments. This would give patients better chances.

This study shows that calretinin might help predict how someone with this cancer might do, opening new ways to make treatments better.

This research tells us how important calretinin is in this cancer. It’s not only for finding the cancer. It might also help predict how long someone might live with mesothelioma. And it should show how well they might respond to treatment. It tells us we need to study more about calretinin to make better and more personalized treatments for people with malignant mesothelioma.

Source:

Zupanc, Cita, Alenka Franko, Danijela Štrbac, Viljem Kovač, Vita Dolžan, and Katja Goričar. “Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma.” International Journal of Molecular Sciences 25, no. 1 (January 2024): 190. https://doi.org/10.3390/ijms25010190.

Similar Posts

  • | |

    Doctors Describe "Concrete Therapeutic Approach" for Mesothelioma

    ByAlex Strauss

    A team of medical researchers in Italy have achieved what they are calling “excellent” tumor control and survival results in malignant pleural mesothelioma patients using a combination of surgery, chemotherapy, and radiotherapy. Caused by exposure to asbestos, mesothelioma typically spreads quickly across the lung-encasing membrane called the pleura. There is no known cure but treatments are improving. In the current prospective study, 20 malignant pleural mesothelioma patients underwent radical pleurectomy/decortication followed by high doses of radiation. After surgeons removed as much of the visible mesothelioma tumor and surrounding tissue as possible, patients received 50Gy of radiation to the effected side of their chest, delivered in 25 fractions. Regions of particular concern for mesothelioma regrowth got an extra radiation “boost” to…

  • | |

    A Second-Line Option for Mesothelioma?

    ByAlex Strauss

    Although survival was not significantly extended, the chemotherapy drug vinorelbine might be a treatment option for mesothelioma patients whose cancer has returned after first-line chemotherapy with pemetrexed. A new study on vinorelbine as a second-line treatment finds that the drug is “moderately active” in mesothelioma patients who were initially treated with pemetrexed-based chemotherapy. Pemetrexed (Alimta), along with a platinum-based drug like cisplatin, is the primary first-line drug therapy for mesothelioma. But vinorelbine is gaining attention as a possible option for mesothelioma, in part because it is available in a less expensive generic form. In “Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma”, the Italian authors detail the results of their study on 59 patients with unresectable pleural mesothelioma.  These patients…

  • | |

    Mesothelioma Surgery May Have Added Benefit

    ByAlex Strauss

    Cancer researchers at Wake Forest University have found another benefit to the cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) combination used to treat peritoneal mesothelioma and other abdominal cancers: the control of fluid buildup. Fluid accumulation in the abdomen because of peritoneal mesothelioma or another type of cancer is known as ascites. Left untreated, ascites can cause bloating, discomfort, disfiguration, and shortness of breath when it interferes with the movement of the diaphragm. While patients with peritoneal mesothelioma, an aggressive cancer of the peritoneal surface, can have this fluid drained off, it often reaccumulates. But the new Wake Forest research suggests that CRS/HIPEC may offer a more permanent solution. Fifteen percent of the cancer patients in the study had…

  • | |

    Mesothelioma Study Cites Risks & Benefits of Second Surgery

    ByAlex Strauss

    Peritoneal mesothelioma patients who have cytoreductive surgery (CRS) and heated chemotherapy can sometimes benefit from a second surgery, but it may be harder the second time around. Researchers in France have recently published their findings in a study of patients with mesothelioma and other peritoneal cancers who experienced recurrence after  cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Peritoneal mesothelioma is an asbestos-related malignancy that spreads across the peritoneum, the membrane that lines the abdomen. For patients who are healthy enough to undergo it, cytoreductive surgery to remove as much of the cancer as possible, followed by a solution of heated chemotherapy drugs, has been shown to improve survival. But the French team wanted to examine the possible options for people…

  • | |

    Unusual Chemo Side Effects in One Mesothelioma Patient

    ByAlex Strauss

    Swiss researches are reporting unusual side effects in one patient arising from mesothelioma treatment with the popular chemotherapy drug pemetrexed. One of the side effects is potentially life-threatening. Approved by the FDA in 2004 and sold under the brand name Alimta, pemetrexed was the first drug developed specifically for the treatment of malignant mesothelioma. Four years later, it was also approved for the treatment of lung cancer. Pemetrexed is a folate antimetabolite that inhibits certain key enzymes and prevents the formation of DNA and RNA critical for mesothelioma cells to function and replicate. It is most often combined with a platinum-based drug like cisplatin or carboplatin in the treatment of mesothelioma. In a report in the journal Lung Cancer, doctors from…

  • | |

    Mesothelioma Chemotherapy Tested

    ByAlex Strauss

    A clinical trial in Japan is testing the theory that high levels of chemotherapy delivered before other treatments may pave the way for more successful mesothelioma surgery. The administration of very high levels of chemotherapy drugs as a first-line cancer treatment is known as induction chemotherapy. The goal of induction chemotherapy is to kill most of the cancer cells up front, reducing or even eliminating the need for further rounds of chemotherapy or other types of treatment. Because mesothelioma is such a virulent cancer, even induction chemotherapy is not usually enough to kill all of the cancer. But the Japanese researchers believe it may be enough to dramatically improve surgical outcomes. When the 2-year trial, which began in September 2012,…